22 recruiting, 13 completed, 7 withdrawn, 6 not yet recruiting. 53 Phase 2, 7 Phase 1, 2 Phase 3.
Follow Opioid Use Disorder: new trials by email Literature Review of Opioid Use Disorder trials Research Report on Opioid Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dynamic Treatment Regimes for Opioid Use Disorder Medication for opioid use disorder, psychotherapy - Opioid Use Disorder | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 75 | 2028-07-01 | 2025-11-04 |
| Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 1 / Phase 2 | Not yet recruiting | Clive Michelsen | 60 | 2027-07-01 | 2026-10-13 |
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder Psilocybin - Opioid Use Disorder | Phase 2 | Withdrawn | Johns Hopkins University | 2027-04-01 | 2026-02-23 | |
| Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons naltrexone implant - Opioid Use Disorder | Phase 2 | Not yet recruiting | Go Medical Industries Pty Ltd | 250 | 2027-01-01 | 2026-09-28 |
| A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain Cebranopadol, Placebo - Chronic Pain, Pain | Phase 2 | Recruiting | Adneuris Therapeutics, Inc. | 45 | 2026-10-01 | 2026-10-23 |
| Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder Yohimbine + Hydrocortisone, Active rTMS, Placebo - Opioid Use Disorder | Phase 2 | Not yet recruiting | Wayne State University | 20 | 2026-10-01 | 2025-12-30 |
| Ketones for Opioid Craving Treatment with Ketone Supplement, Treatment with Placebo - Opioid Use Disorder | Phase 2 | Recruiting | University of Maryland, Baltimore | 50 | 2026-07-16 | 2026-08-25 |
| Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual Buprenorphine SL, Telehealth, In-person treatment as usual - Opioid Use Disorder | Phase 2 | Withdrawn | New York State Psychiatric Institute | 2026-06-01 | 2026-09-08 | |
| A Study of Brenipatide in Participants With Opioid Use Disorder Brenipatide, Placebo, Buprenorphine - Opioid Use Disorder | Phase 2 | Recruiting | Eli Lilly and Company | 465 | 2026-02-13 | 2026-11-04 |
| Ketamine for Opioid Use Disorder Treatment with Ketamine, Treatment with Very Low Dose Ketamine - Opioid Use Disorder | Phase 2 | Recruiting | University of Maryland, Baltimore | 50 | 2026-02-04 | 2026-10-20 |
| Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement Ketamine, Mindfulness-Oriented Recovery Enhancement (MORE), Support Group - Opioid Use Disorder | Phase 2 | Not yet recruiting | University of California, San Diego | 88 | 2026-02-01 | 2026-02-03 |
| Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder Tirzepatide, Placebo - Opioid Use Disorder, Opioid Use Disorder, Moderate | Phase 2 | Recruiting | T. John Winhusen, PhD | 310 | 2026-01-29 | 2026-08-11 |
| Psilocybin on Brain Mechanisms of Motivation in OUD Psilocybin (high dose), psilocybin (low dose) - Opioid Use Disorder | Phase 2 | Recruiting | University of Pennsylvania | 24 | 2025-12-22 | 2026-07-09 |
| Psilocybin for Opioid Use Disorder (OUD) Psilocybin - Opioid Use Disorder | Phase 2 | Recruiting | NYU Langone Health | 480 | 2025-12-17 | 2026-01-23 |
| Extended-release Buprenorphine as a Novel Low-dose Induction Strategy Extended-release Buprenorphine - Opioid Use Disorder | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 8 | 2025-10-27 | 2026-07-09 |
| Wellcome Leap Psilocybin for OUD Psilocybin - Opioid Use Disorder | Phase 2 | Recruiting | Anna Rose Childress, Ph.D. | 36 | 2025-10-07 | 2025-10-29 |
| Semaglutide for Helping Opioid Recovery Semaglutide, Placebo - Opioid Use Disorder | Phase 2 | Recruiting | Brigham and Women's Hospital | 46 | 2025-06-02 | 2026-10-13 |
| Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects Placebo, Lemborexant 10 MG - Opioid Use Disorder, Opioid Use | Phase 2 | Recruiting | Virginia Commonwealth University | 100 | 2025-05-27 | 2026-07-09 |
| Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use Buprenorphine - Opioid Use Disorder | Phase 2 | Recruiting | University of Pennsylvania | 60 | 2025-05-08 | 2026-07-10 |
| GLP-1R Agonist Treatment for Opioid Use Disorder Semaglutide Pen Injector, Placebo - Opioid Use Disorder, Opioid Abuse and Addiction | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 200 | 2025-01-27 | 2026-08-28 |
Showing 20 of 53. Sign in to see all of them.
Opioid-Related Disorders (53) · Substance-Related Disorders (6) · Behavior, Addictive (4) · Chronic Pain (4) · Pain (4) · Chemically-Induced Disorders (2) · Heroin Dependence (2) · Marijuana Abuse (2) · Narcotic-Related Disorders (2) · Recurrence (2) · Sleep Initiation and Maintenance Disorders (2) · Acquired Immunodeficiency Syndrome (1) · Alcoholism (1) · Anxiety Disorders (1) · Cigarette Smoking (1)
Mental Disorders (52) · Chemically-Induced Disorders (51) · Narcotic-Related Disorders (51) · Substance-Related Disorders (47) · Pathological Conditions, Signs and Symptoms (8) · Behavior (7) · Neurologic Manifestations (6) · Signs and Symptoms (6) · Compulsive Behavior (4) · Impulsive Behavior (4) · Disease Attributes (2) · Dyssomnias (2) · Health Behavior (2) · Immune System Diseases (2) · Nervous System Diseases (2)
Buprenorphine (8) · Psilocybin (6) · Buprenorphine, Naloxone Drug Combination (4) · Cannabidiol (4) · Hydromorphone (4) · Ketamine (3) · lofexidine (3) · Naloxone (2) · Saline Solution (2) · Therapeutics (2) · lemborexant (2) · semaglutide (2) · suvorexant (2) · 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine (1) · ASP8062 (1)
Johns Hopkins University (6) · University of Maryland, Baltimore (5) · Brigham and Women's Hospital (4) · New York State Psychiatric Institute (4) · University of Pennsylvania (3) · Virginia Commonwealth University (3) · Indivior Inc. (2) · NYU Langone Health (2) · Rhode Island Hospital (2) · Wayne State University (2) · Yasmin Hurd (2) · Adneuris Therapeutics, Inc. (1) · Anna Rose Childress, Ph.D. (1) · Astellas Pharma Global Development, Inc. (1) · BC Centre on Substance Use (1)
United States (46) · Canada (3) · Puerto Rico (1) · United Kingdom (1)
Peter Manza, PhD (2) · Sandeep Nayak, MD (2) · Sandra D Comer, PhD (2) · Yasmin Hurd, PhD (2) · Adam Bisaga, MD (1) · Albert Arias, MD (1) · Andrew S Huhn, Ph.D. (1) · Anna Rose Childress, PhD (1) · Caitlin E Martin, MD (1) · Cecilia Bergeria, Ph.D. (1) · Cecilia L Bergeria, PhD (1) · Charles Nwaokobia (1) · Christina Brezing, MD (1)
PMID 15734224, PMID 25563446, PMID 25784600, PMID 26650971, PMID 27010975, PMID 30091969, PMID 30944474, PMID 31065731, PMID 31681040, PMID 32098487, PMID 33579359, PMID 33601929, PMID 33972795, PMID 36467036, PMID 37584841, PMID 38528704, PMID 39521460, PMID 40046866, PMID 40502777, PMID 41151943, PMID 41168808, PMID 42113179
1UG3DA062088-01 (1), 4UH3DA047720-03 (1), 5UG1DA050207 (1), K01DA061975 (1), R01DA052937 (1), R01DA056045 (1), R01DA059483 (1), R01DA060066 (1), R21DA055835 (1), R44DA056156 (1), U54DA037842 (1), UG1DA013732 (1), UG1DA050207 (1), UG3DA056247-01 (1), UH3DA048734 (1)